Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by bringon10baggeron Oct 19, 2019 4:45pm

125 Views

Post# 30247737

RE:RE:RE:RE:3 catalysts to push SP higher

I kinda like the timing of news release of trial results late Q4 and in anticipation of them being positive, won't be too much selling for tax loss purpose......strategic possibly?

Nextstepinvest wrote: According to the guidelines and historical precedent, it takes 3-4 weeks to process the trial results after the last person finishes the trial. So the timeline goes: NR- enrollment of final patient- 2 weeks remaining of trial, and then 4 weeks after the patient finishes the trial (6 weeks after last NR) primary endpoints results will be released in an NR. So we're looking at early-mid november for last enrollment, mid-late december for results

Bullboard Posts

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide